Meet: Tobi Nagel - Phages for Global Health
Full Bio: Dr. Tobi Nagel is Founder and President of Phages for Global Health, a non-profit organization that facilitates the application of antibacterial phages to combat antimicrobial resistance in developing countries. Before launching Phages for Global Health, Tobi had 15 years experience in the pharmaceutical industry (including Novartis, Silver Creek Pharmaceuticals and Genentech/Roche), where she worked with international teams to co-develop products that have been tested in over 80 clinical trials worldwide. She previously completed a Postdoctoral Fellowship at the American Hospital in Istanbul, Turkey, partnering with the University of California at San Francisco and Baylor College of Medicine. Tobi is currently a member of the Fulbright Specialist program, focusing on building scientific infrastructure in developing countries. She is also a Scientific Advisory Board Member of the Phagebiotics Research Foundation and was selected as an Advisory Panel Member for the Phages for Human Applications Group Europe (P.H.A.G.E). Over the past 10 years she has served as a Scientific Consultant for both Global Strategies for HIV Prevention and CRDF Global, facilitating capacity development and technology transfer in international settings. Tobi holds a PhD in Medical Engineering from the joint Harvard-MIT Division of Health Sciences and Technology and a Bachelor of Science in Chemical Engineering from Stanford University.
Work Description: Phages for Global Health aims to bring phage expertise to the developing world, through two main programs. They conduct laboratory training workshops and product development projects to facilitate the application of antibacterial phage technology. With two major projects, based in Kenya and the Democratic Republic of Congo respectively, the organization has brought together two teams of international collaborators to co-develop phage products for important public health applications. As the founder and president of the organization, Dr Tobi Nagel goal is to decrease the 2050 estimate of 10 million deaths each year from antibiotic resistant infections, especially in the developing world.